Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M347Revenue $M7.9Net Margin (%)-541.5Z-Score1.3
Enterprise Value $M253EPS $-0.8Operating Margin %-546.7F-Score3
P/E(ttm))0Cash Flow Per Share $0.4Pre-tax Margin (%)-546.1Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %0Quick Ratio23.9Cash flow > EarningsY
Price/Sales40.25-y EBITDA Growth Rate %0Current Ratio23.9Lower Leverage y-yN
Price/Cash Flow6.4y-y EBITDA Growth Rate %0ROA % (ttm)-37.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-53.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M69.6ROI % (ttm)-48.7Gross Margin Increase y-yN

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PGNXJohn Hussman 2009-06-30 Sold Out -0.02%$4.53 - $6.84
($5.48)
$ 4.99-9%Sold Out0
PGNXJohn Hussman 2008-09-30 Buy 0.04%$12.19 - $17.07
($14.9)
$ 4.99-66%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PGNX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISRAEL ROBERT JSenior VP Medical Affairs 2013-07-18Sell5,000$6.33-23.06 view
Baker Mark RobertCEO 2013-03-27Buy650$5.32-8.46 view
Baker Mark RobertCEO 2013-02-27Buy1,262$2.7279.04 view
Baker Mark RobertCEO 2013-01-22Buy1,215$2.8272.7 view
Baker Mark RobertCEO 2012-12-26Buy1,142$3.0161.79 view
Baker Mark RobertCEO 2012-11-28Buy1,607$2.13128.64 view
Baker Mark RobertCEO 2012-11-19Buy11,800$1.96148.47 view
Baker Mark RobertCEO 2012-11-16Buy49,793$1.82167.58 view
Baker Mark RobertCEO 2012-11-15Buy48,833$1.69188.17 view
Baker Mark RobertCEO 2012-10-24Buy1,162$2.9664.53 view

Press Releases about PGNX :

    Quarterly/Annual Reports about PGNX:

    News about PGNX:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
    Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
    Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
    5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
    Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
    Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 
    Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Sep 02 2010 

    More From Our Partners
    Progenics-Salix Up on Encouraging Relistor News - Analyst Blog Jul 15 2014 - ZACKS

    More From Other Websites
    Progenics (PGNX) Shares March Higher, Can It Continue? Jul 22 2014
    An Inefficient Stock Market Will Catch Up To Progenics Jul 21 2014
    Progenics-Salix Up on Encouraging Relistor News Jul 15 2014
    Biotechs, social stocks weak after Yellen warning Jul 15 2014
    Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% Jul 15 2014
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 14 2014
    FDA Office of Drug Evaluation III Approves Salix's Request that the FDA Approve the RELISTOR®... Jul 14 2014
    Midday movers: Citigroup, Newmont Mining & More Jul 14 2014
    Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for... Jul 14 2014
    UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA... Jul 14 2014
    Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for... Jul 14 2014
    FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR®... Jul 14 2014
    Another good find in specialty pharma Jul 03 2014
    PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 18 2014
    What Does A Positive Adcom Mean For Progenics And Salix? Jun 17 2014
    [$$] Two Undervalued Biopharmas to Buy Now Jun 13 2014
    Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% Jun 13 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide